FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to pharmaceutics and medicine and concerns an antigen structure and pharmaceutical composition containing it, used for therapeutic and diagnostic application in treating diseases and disorders caused by or associated with neurofibrillar plexuses. Particularly, the claim describes a pharmaceutical composition containing an antigen peptide, preferentially an antigen phosphorylated peptide simulating a primary pathological phosphor-epitope of tau-protein applicable for therapeutic and diagnostic application for treating taupathies, including Alzheimer disease.
EFFECT: group of inventions provides producing a high-specific immune response in the body and makes it possible to prevent or relieve taupathies or taupathy-related diseases.
34 cl, 11 ex, 15 tbl, 37 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2011 |
|
RU2603078C2 |
| METHOD OF USE IN THERAPY | 2010 |
|
RU2579659C2 |
| PHOSPHO-SPECIFIC ANTIBODIES RECOGNIZING TAU | 2012 |
|
RU2639537C2 |
| ANTIBODIES, SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2727911C2 |
| THERAPEUTIC VACCINE | 2006 |
|
RU2440824C2 |
| ANTIBODIES SPECIFIC TO HYPERPHOSPHORYLATED TAU-PROTEIN AND THEIR APPLICATION METHODS | 2017 |
|
RU2760875C1 |
| THERAPEUTIC AGENT OR PROPHYLACTIC AGENT FOR DEMENTIA | 2013 |
|
RU2657438C2 |
| THERAPY AND DIAGNOSTICS BASED ON PROTEINS OF TAU-MEDIATED PATHOLOGY IN ALZHEIMER DISEASE | 2012 |
|
RU2645259C2 |
| ANTIGEN TAU-PEPTIDES AND THEIR APPLICATION | 2010 |
|
RU2518291C2 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
